Toggle light / dark theme

Astroscale raised an additional funding of $51 million from a group of investors, bringing the total capital raised to $191 million, the Japanese orbital debris removal company said today.
This latest round makes Astroscale the most funded on-orbit services and logistics company globally and most funded space venture in Japan, the Tokyo-based company said.

The investment raised since its founding in 2013 has allowed Astroscale to establish a global footprint across five countries and grow to over 140 team members, Astroscale said. “Each of the five global offices are working in concert to achieve the Astroscale mission of safe and sustainable development of space for future generations.”


Luxembourg, 13 October 2020. – Astroscale raised an additional funding of $51 million from a group of investors, bringing the total capital raised to $191 million, the Japanese orbital debris removal company said today.

Eli Lilly (NYSE: LLY) reportedly paused a clinical trial testing its COVID-19 antibody treatment candidate because of a “potential safety concern.”

The New York Times reported that Eli Lilly’s testing site researchers were notified of the pause by emails sent by government officials (it is a government-sponsored trial) and the company later confirmed it. A spokesperson from the company told The Hill that “Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.”

Eli Lilly’s trial was comparing its therapy to a placebo, while all study participants also received the experimental drug remdesivir, which has been used in treating COVID-19 throughout the pandemic. The company’s therapeutic uses monoclonal antibodies in an effort to block the virus from infecting cells.

In 1978, NASA scientist Donald Kessler warned of a potential catastrophic, cascading chain reaction in outer space. Today known as “Kessler Syndrome,” the theory posited that space above Earth could one day become so crowded, so polluted with both active satellites and the detritus of space explorations past, that it could render future space endeavors more difficult, if not impossible.

Last week, the CEO of Rocket Lab, a launch startup, said the company is already beginning to experience the effect of growing congestion in outer space.

Rocket Lab CEO Peter Beck said that the sheer number of objects in space right now — a number that is growing quickly thanks in part to SpaceX’s satellite internet constellation, Starlink — is making it more difficult to find a clear path for rockets to launch new satellites.

GE Healthcare has received 510k clearance from US FDA for its Ultra Edition package on Vivid cardiovascular ultrasound systems, which come with features based on artificial intelligence (AI) that allows clinicians to get quicker and more exams repeatedly. Although methodical evaluations of heart function are necessary in echocardiography, such evaluations can be time-consuming and difficult to get. Quality acquisition of data and operator skill are essential factors to get precise and thorough exams. Given that patients undergo subsequent monitoring exams, the reproducibility of the exam evaluations is essential to monitoring improvement or progress of the disease.

Flexible spikes

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein enables viral entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor and is a major target for neutralizing antibodies. About 20 to 40 spikes decorate the surface of virions. Turoňová et al. now show that the spike is flexibly connected to the viral surface by three hinges that are well protected by glycosylation sites. The flexibility imparted by these hinges may explain how multiple spikes act in concert to engage onto the flat surface of a host cell.

Science, this issue p. 203.


By Beata Turoňová, Mateusz Sikora, Christoph Schürmann, Wim J. H. Hagen, Sonja Welsch, Florian E. C. Blanc, Sören von Bülow, Michael Gecht, Katrin Bagola, Cindy Hörner, Ger van Zandbergen, Jonathan Landry, Nayara Trevisan Doimo de Azevedo, Shyamal Mosalaganti, Andre Schwarz, Roberto Covino, Michael D. Mühlebach, Gerhard Hummer, Jacomine Krijnse Locker, Martin Beck.

If Dr. Ken Berry actually meant to say that you need to eat saturated fat for your nerves and brain, he flunks Biochem 101. First of all, your body can make all the saturated fat you need out of carbs and proteins. You don’t need to eat ANY saturated fat. Second, the most common fatty acid in your brain is the polyunsaturated fatty acid (PUFA) called DHA, which you DO need to eat, because you can’t make it from non-fats (you need to eat it or EPA in things like seafood, or at least the precursor omega-3 PUFA called ALA in cold-climate plants.) Ironically enough, ALA is common in Canola oil, which Dr. Berry deprecates, but not in the tropical plant oils that he likes. More on that later.

A diet with a lot of saturated fat is NOT the best for the heart. The American Heart Association continues to recommend low saturated fat diets (with the missing sat-fat replaced by mono and polyunsaturated fat, not by carbohydrates) because the evidence from animal and human trials and even properly controlled epidemiology, shows these the best diets (see reference below—an extensive review of meta analyses [1]). Examples are the DASH hypertension diet and the closely-related Mediterranean diet (which has lots of olive oil for monounsaturated fatty acid, and seafood for DHA). If Dr. Berry thinks he has something better than the Mediterranean diet for longevity, what is his direct evidence?

Saturated fat, of course, is used by the body to make cholesterol (you don’t need to eat any cholesterol for this reason), and it does raise cholesterol levels and it does increase atherosclerosis in nearly every controlled prospective experimental model in animals and humans. This is the gold standard of evidence in medicine.

One can go only so far with epidemiology, because occasionally when one bad thing (saturated fat) is heavily replaced for calories by another bad thing (certain carbohydrates) one detects no epidemiologic effect from changing just the first thing.

That happens with various high and low saturated fat diets around the world enough to make saturated fat look benign as a single input variable. It is not. Rather, what these studies really show is that replacing butter with sugar or high glycemic carbs gives you a diet equally bad for the arteries. One cannot see how bad that is, until one compares these with low-carbohydrate, low-saturated-fat diets, which are less common, but better. The double-negative tradeoff of carbs and saturated fats (where carbs are a statistical “confounder”) is one of those occasional cruel misdirectional things that happen with imperfectly controlled past-observations, but (again) it’s why biomedical knowledge consists of more than just epidemiology.

Interesting Eric Klien


That prompted the researchers, who are part of the Human Brain Project, to look at two features that have become clear in experimental neuroscience data: each neuron retains a memory of previous activity in the form of molecular markers that slowly fade with time; and the brain provides top-down learning signals using things like the neurotransmitter dopamine that modulates the behavior of groups of neurons.

In a paper in Nature Communications, the Austrian team describes how they created artificial analogues of these two features to create a new learning paradigm they call e-prop. While the approach learns slower than backpropagation-based methods, it achieves comparable performance.

More importantly, it allows online learning. That means that rather than processing big batches of data at once, which requires constant transfer to and from memory that contributes significantly to machine learning’s energy bills, the approach simply learns from data as it becomes available. That dramatically cuts the amount of memory and energy it requires, which makes it far more practical to use for on-chip learning in smaller mobile devices.